Literature DB >> 15353984

Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

Jade Ghosn1, Marie-Laure Chaix, Gilles Peytavin, Elisabeth Rey, Jean-Louis Bresson, Cécile Goujard, Christine Katlama, Jean-Paul Viard, Jean-Marc Tréluyer, Christine Rouzioux.   

Abstract

One likely mechanism of virological failure is poor antiretroviral drug diffusion in sites of viral replication such as the genital tract. We measured antiretroviral drug concentrations in blood and semen in 13 HIV-infected men failing treatment. Enfuvirtide did not cross the blood-testis barrier, whereas tenofovir accumulated in semen. Unlike indinavir, semen concentrations of lopinavir, amprenavir, saquinavir and efavirenz were ineffective. These are worrying findings, because suboptimal semen drug concentrations may enhance the risk of sexually transmitted drug-resistant HIV variants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353984     DOI: 10.1097/00002030-200409240-00014

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  34 in total

1.  Antiretroviral therapy as HIV prevention: status and prospects.

Authors:  Kenneth H Mayer; Kartik K Venkatesh
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

2.  Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.

Authors:  Julie B Dumond; Kuo H Yang; Racheal Kendrick; Y Sunila Reddy; Angela D M Kashuba; Luigi Troiani; Arlene S Bridges; Susan A Fiscus; Alan Forrest; Myron S Cohen
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

Review 3.  Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.

Authors:  Douglas Krakower; Kenneth H Mayer
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

4.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.

Authors:  Christine Goffinet; Ina Allespach; Oliver T Keppler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-05       Impact factor: 11.205

6.  A mechanistic latent variable model for estimating drug concentrations in the male genital tract: a case study in drug kinetics.

Authors:  Leena Choi; Brian Caffo; Charles Rohde; Themba T Ndovi; Craig W Hendrix
Journal:  Stat Med       Date:  2008-06-30       Impact factor: 2.373

7.  Determinants of HIV shedding in the lower genital tract of women.

Authors:  Brenna L Anderson; Susan Cu-Uvin
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

Review 8.  Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Authors:  Christine R Trezza; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

9.  Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.

Authors:  Richard W Price; Robin Parham; Jing Lu Kroll; Stephen A Wring; Brian Baker; Jeff Sailstad; Rebecca Hoh; Teri Liegler; Serena Spudich; Daniel R Kuritzkes; Steven G Deeks
Journal:  Antivir Ther       Date:  2008

10.  Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.

Authors:  E van Leeuwen; R Ter Heine; F van der Veen; S Repping; J H Beijnen; J M Prins
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.